Divergent role for CRF1 and CRF2 receptors in the modulation of visceral pain

Neurogastroenterology and Motility

Volumn 17, Issue 3, 2005, Pages 423-432

  Nijsen, M ^a,b   Ongenae, N ^a   Meulemans, A ^a   Coulie, B ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Janssen Pharmaceutica ^*  (Belgium)

Author keywords

Antinociception; Irritable bowel syndrome; Pro nociception; Stress

Indexed keywords

ANTISAUVAGINE 30; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; PEPTIDE DERIVATIVE; STRESSCOPIN RELATED PEPTIDE; UNCLASSIFIED DRUG; UROCORTIN III; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRF RECEPTOR TYPE 1; CRF RECEPTOR TYPE 2;

ABDOMINAL WALL MUSCULATURE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTROMYOGRAM; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; VISCERAL PAIN; ANIMAL; BALLOON DILATATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; DUODENUM; ELECTRODE; ELECTROMYOGRAPHY; NOCICEPTIVE RECEPTOR; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; STIMULATION; TELEMETRY; WISTAR RAT;

ANIMALS; BALLOON DILATATION; BEHAVIOR, ANIMAL; CORTICOTROPIN-RELEASING HORMONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DUODENUM; ELECTRODES, IMPLANTED; ELECTROMYOGRAPHY; MALE; NOCICEPTORS; PAIN; PHYSICAL STIMULATION; RATS; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; TELEMETRY;

EID: 20044383206     PISSN: 13501925     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2005.00644.x     Document Type: Article

References (55)

1. Munakata J, Naliboff B, Harraf F et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997; 112: 55-63.
2. Kellow JE, Eckersley CM, Jones MP. Enhanced perception of physiological intestinal motility in the irritable bowel syndrome. Gastroenterology 1991; 101: 1621-7.
3. Accarino AM, Azpiroz F, Malagelada JR. Attention and distraction: effects on gut perception. Gastroenterology 1997; 113: 415-22.
4. Ford MJ, Camilleri M, Zinsmeister AR, Hanson RB. Psychosensory modulation of colonic sensation in the human transverse and sigmoid colon. Gastroenterology 1995; 109: 1772-80.
5. Hislop IG. Psychological significance of the irritable colon syndrome. Gut 1971; 12: 452-7.
6. Bennett EJ, Tennant CC, Piesse C, Badcock CA, Kellow JE. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998; 43: 256-61.
7. Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 1992; 33: 825-30.
8. Gue M, Rio-Lacheze C, Eutamene H, Theodorou V, Fioramonti J, Bueno L. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol Motil 1997; 9: 271-9.
9. Million M, Grigoriadis DE, Sullivan S et al. A novel water-soluble selective CRF(1) receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats. Brain Res 19; 2003: 32-42.
10. Van Pett K, Viau V, Bittencourt JC et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 2000; 428: 191-212.
11. Jagoda E, Contoreggi C, Lee MJ et al. Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2. J Med Chem 2003; 46: 3559-62.
12. Sanchez MM, Young LJ, Plotsky PM, Insel TR. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol 1999; 408: 365-77.
13. Dautzenberg FM, Hauger RL. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 2002; 23: 71-7.
14. Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM. International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev 2003; 55: 21-6.
15. Kawahito Y, Sano H, Kawata M et al. Local secretion of corticotropin-releasing hormone by enterochromaffin cells in human colon. Gastroenterology 1994; 106: 859-65.
16. Muramatsu Y, Fukushima K, Iino K et al. Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa. Peptides 2000; 21: 1799-809.
17. Nieuwenhuijzen Kruseman AC, Linton EA, Lowry PJ, Rees LH, Besser GM. Corticotropin-releasing factor immunoreactivity in human gastrointestinal tract. Lancet 1982; 2: 1245-6.
18. Chatzaki E, Charalampopoulos I, Leontidis C et al. Urocortin in human gastric mucosa: relationship to inflammatory activity. J Clin Endocrinol Metab 2003; 88: 478-83.
19. Kozicz T, Arimura A. Distribution of urocortin in the rat's gastrointestinal tract and its colocalization with tyrosine hydroxylase. Peptides 2002; 23: 515-21.
20. Dautzenberg FM, Kilpatrick GJ, Hauger RL, Moreau J. Molecular biology of the CRH receptors in the mood. Peptides 2001; 22: 753-60.
21. Perrin MH, Vale WW. Corticotropin releasing factor receptors and their ligand family. Ann NY Acad Sci 1999; 20: 312-28.
22. Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998; 42: 845-9.
23. Lembo T, Plourde V, Shui Z et al. Effects of the corticotropin-releasing factor (CRF) on rectal afferent nerves in humans. Neurogastroenterol Motil 1996; 8: 9-18.
24. Song ZH, Takemori AE. Involvement of spinal kappa opioid receptors in the antinociception produced by intrathecally administered corticotropin-releasing factor in mice. J Pharmacol Exp Ther 1990; 254: 363-8.
25. Kita A, Imano K, Nakamura H. Involvement of corticotropin-releasing factor in the antinociception produced by interleukin-1 in mice. Eur J Pharmacol 1993; 237: 317-22.
26. Seymour PA, Schmidt AW, Schulz DW. The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor, a review, CNS. Drug Rev 2003, 9: 57-96.
27. Lawrence AJ, Krstew EV, Dautzenberg FM, Ruhmann A. The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain. Br J Pharmacol 2002; 136: 896-904.
28. Brauns O, Brauns S, Jenke M, Zimmermann B, Dautzenberg F. Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity. Peptides 2002; 23: 1817-27.
29. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001; 7: 605-11.
30. Colburn RW, Coombs DW, Degnan CC, Rogers LL. Mechanical visceral pain model: chronic intermittent intestinal distention in the rat. Physiol Behav 1989; 45: 191-7.
31. Ness TJ, Gebhart GF. Colorectal distention as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudoaffective reflexes in the rat. Brain Res 1988; 450: 153-69.
32. Nijsen MJ, Ongenae NG, Coulie B, Meulemans AL. Telemetric animal model to evaluate visceral pain in the freely moving rat. Pain 2003; 105: 115-23.
33. Schwetz I, Bradesi S, McRoberts JA et al. Delayed stress-induced colonic hypersensitivity in male Wister rats: role of neurokinin-1 and corticotropin-releasing factor-1 receptors. Am J Physiol Gastrointest Liver Physiol 2004; 286: G683-91.
34. Million M, Wang L, Tache' Y. Human urocortin II (hUcn II) blunts colorectal distention induced visceromotor response and activation of ERK in spinal neurons of rats. Gastroenterology 2003; 124: A46.
35. 2 agonist, prevents colorectal distention-induced visceral pain in rats. Gastroenterology 2002; 122: A-257.
36. Tache Y, Monnikes H, Bonaz B, Rivier J. Role of CRF in stress-related alterations of gastric and colonic motor function. Ann NY Acad Sci 1993; 697: 233-43.
37. Tache Y, Martinez V, Million M, Wang L. Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am J Physiol Gastrointest Liver Physiol 2001; 280: G173-7.
38. Martins JM, Kastin AJ, Banks WA. Unidirectional specific and modulated brain to blood transport of corticotropin-releasing hormone. Neuroendocrinology 1996; 63: 338-48.
39. Miampamba M, Maillot C, Million M, Tache Y, Peripheral CRF. activates myenteric neurons in the proximal colon through CRF(1) receptor in conscious rats. Am J Physiol Gastrointest Liver Physiol 2002; 282: G857-G865.
40. Lovenberg TW, Chalmers DT, Liu C, De Souza EB. CRF2α and CRF2β receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 1995; 136: 4139-42.
41. Radulovic M, Spiess J. Immunomodulatory role of the corticotropin- releasing factor. Arch Immunol Ther Exp (Warsz) 2001; 49: 33-8.
42. Million M, Sanchez-Watts G, Saunders P et al. CRF receptor subtypes 1 and 2 are expressed in the colonic tissue of the rat. Gastroenterology 2002; 122: A-524.
43. Reul JM, Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2002; 2: 23-33.
44. Liu S, Gao X, Gao N et al. Expression of receptors for corticotropin releasing factor in guinea pig enteric nervous system. Gastroenterology 2003; 124: A23.
45. Dieterich KD, Lehnert H, De Souza EB. Corticotropin-releasing factor receptors: an overview. Exp Clin Endocrinol Diabetes 1997; 105: 65-82.
46. Primus RJ, Yevich E, Baltazar C, Gallager DW. Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain. Neuropsychopharmacology 1997; 17: 308-16.
47. Grigoriadis DE, Lovenberg TW, Chalmers DT, Liaw C, De Souza EB. Characterization of corticotropin-releasing factor receptor subtypes. In: Crawley JN, McLean S, eds. Annals of the New York Academy of Sciences; Neuropeptides: Basic and Clinical Advances. New York, NY, USA: New York Academy of Sciences 1996: 60-80.
48. Chalmers DT, Lovenberg TW, De Souza EB. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci 1995; 15: 6340-50.
49. Martinez V, Tache Y. Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats. Brain Res 2001; 893: 29-35.
50. Nozu T, Martinez V, Rivier J, Tache Y. Peripheral urocortin delays gastric emptying: role of CRF receptor 2. Am J Physiol 1999; 276: G867-74.
51. Million M, Maillot C, Saunders P, Rivier J, Vale W, Tache Y. Human urocortin II, a new CRF-related peptide, displays selective CRF(2)-mediated action on gastric transit in rats. Am J Physiol Gastrointest Liver Physiol 2002; 282: G34-40.
52. Chen CY, Million M, Adelson DW, Martinez V, Rivier J, Tache Y. Intracisternal urocortin inhibits vagally stimulated gastric motility in rats: role of CRF(2). Br J Pharmacol 2002; 136: 237-47.
53. Martinez V, Wang L, Rivier JE, Vale W, Tache Y. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J Pharmacol Exp Ther 2002; 301: 611-7.
54. Valdez GR, Inoue K, Koob GF, Rivier J, Vale W, Zorrilla EP. Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res 2002; 943: 142-50.
55. Zorrilla E, Valdez G, Nozulak J, Koob G, Markou A. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 2002; 952: 188-99.